Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9275 USD | +6.46% | +5.84% | -13.32% |
03-21 | Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
03-21 | MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 32.18M 2.58B |
---|---|---|---|---|---|
Net income 2024 * | -19M -1.52B | Net income 2025 * | -36M -2.88B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.8
x | P/E ratio 2025 * |
-1.4
x | Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 28.66% |
Latest transcript on MiNK Therapeutics, Inc.
1 day | +6.46% | ||
1 week | +5.84% | ||
Current month | +2.11% | ||
1 month | +1.92% | ||
3 months | +9.97% | ||
6 months | +1.87% | ||
Current year | -13.32% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Buell
CEO | Chief Executive Officer | 50 | 31/01/21 |
Heather Boussios
CMP | Compliance Officer | - | - |
Marc van Dijk
CTO | Chief Tech/Sci/R&D Officer | 61 | 29/02/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garo Armen
CHM | Chairman | 71 | 30/06/17 |
Director/Board Member | 66 | 30/06/17 | |
Barbara Ryan
BRD | Director/Board Member | 64 | 31/08/21 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.9275 | +6.46% | 32,366 |
25/04/24 | 0.8712 | -2.00% | 40,066 |
24/04/24 | 0.889 | +2.07% | 38,552 |
23/04/24 | 0.871 | -2.57% | 97,040 |
22/04/24 | 0.894 | +2.02% | 40,075 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.32% | 32.18M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INKT Stock